Exhibit 5.2
| | | | |
| | 12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com |
| |
![LOGO](https://capedge.com/proxy/S-3/0001193125-23-274478/g541872g1108104545226.jpg) | | FIRM / AFFILIATE OFFICES |
| | Austin | | Milan |
| | Beijing | | Munich |
| | Boston | | New York |
| | Brussels | | Orange County |
| | Century City | | Paris |
November 9, 2023 | | Chicago | | Riyadh |
| | Dubai | | San Diego |
| | Düsseldorf | | San Francisco |
| | Frankfurt | | Seoul |
| | Hamburg | | Silicon Valley |
| | Hong Kong | | Singapore |
| | Houston | | Tel Aviv |
| | London | | Tokyo |
| | Los Angeles | | Washington, D.C. |
| | Madrid | | |
Phathom Pharmaceuticals, Inc.
100 Campus Drive, Suite 102
Florham Park, New Jersey 07932
| Re: | Registration Statement on Form S-3; Shares of Common Stock, par value $0.0001 per share, having an aggregate offering price of up to $150,000,000 |
To the addressee set forth above:
We have acted as special counsel to Phathom Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the sale through Jefferies LLC (“Jefferies”) as the sales agents from time to time by the Company of shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $150,000,000, to be issued pursuant to a registration statement on Form S-3 filed by the Company with the Securities and Exchange Commission (the “Commission”) on November 9, 2023 (the “Registration Statement”), the base prospectus included in the Registration Statement (the “Base Prospectus”) and the related sales agreement prospectus included in the Registration Statement (together with the Base Prospectus, the “Prospectus”), and that certain Open Market Sales Agreement, dated as of November 10, 2020, by and among the Company and Jefferies (the “Sales Agreement”).
The term “Shares” shall include any additional shares of common stock registered by the Company pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Act”), in connection with the offering contemplated by the Registration Statement. This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein with respect to the issue of the Shares.